Reacción
VIEW PDF VERSION
DS-TB treatment PPTCategoría de orientación
Module 4: Treatment and care
Module 4: Treatment and care
Índice (versión en línea) :
- Acknowledgements
- Abbreviations and acronyms
- Definitions
- Executive summary
- Chapter 1. Drug-susceptible TB treatment
-
Chapter 2. Drug-resistant TB treatment
-
Recommendations
- 1. Treatment of drug-resistant TB using 6-month regimens
- 2. Treatment of drug-resistant TB using 9-month regimens
- 3. Treatment of drug-resistant TB using longer regimens
- 4. Treatment of rifampicin-susceptible and isoniazid-resistant TB (Hr-TB)
- 5. Monitoring and management strategies for MDR/RR-TB treatment
- 6. Starting antiretroviral therapy in patients on MDR/RR-TB regimens
- 7. Surgery for patients on MDR/RR-TB treatment
- 8. Hepatitis C virus (HCV) and MDR/RR-TB treatment co-administration
- Research gaps
- References (Chapter 2)
-
Recommendations
- Chapter 3. Tuberculosis care and support
-
Annex 1. Summary of recommendations
- Annex 1.1. Summary of changes to the World Health Organization (WHO) treatment recommendations for drug-susceptible TB (DS-TB) between 2010 and the update and consolidation in 2025
- Annex 1.2. Summary of changes to the World Health Organization (WHO) treatment recommendations for multidrug-resistant or rifampicin-resistant TB (MDR/RR-TB) between 2019 and the update and consolidation in 2025
- Annex 1.3. Summary of changes to the World Health Organization (WHO) treatment recommendations for Tuberculosis care and support between 2011 and the update and consolidation in 2025
- Annex 2. Methods and expert panels
- Annex 3. Declarations of interest
- Annex 4. PICO questions
- Annex 5. GRADE evidence profiles and evidence-to-decision tables
- Annex 6. Statistical analysis plans
- Annex 7. Reports of the systematic reviews for Tuberculosis care and support
Suggested citation. WHO consolidated guidelines on tuberculosis. Module 4: treatment and care. Geneva: World Health Organization; 2025. Licence: CC BY-NC-SA 3.0 IGO.